Latest Docetaxel Stories
-- Ramucirumab Improved Survival in Second-Line Study of Patients with Non-Small Cell Lung Cancer -- INDIANAPOLIS, Feb.
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
The Majority of Current Non-Prescribers Anticipate Prescribing Xofigo within the Next Year, According to Findings from Decision Resources Group BURLINGTON, Mass., Feb.
Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA
- Withering but not falling off, as a blossom that persists on a twig after flowering.